Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 371 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Reference control Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Efficacy of a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation

NCT06933368
View directory record Official record
Conditions
Dental Plaque, Gingivitis
Interventions
Crest Cavity Protection Toothpaste, Experimental Mouthwash
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults

NCT00002204
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
HIV p24/MF59 Vaccine
Biological
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Not applicable Interventional Results available

ABSORB III Randomized Controlled Trial (RCT)

NCT01751906
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
190
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

NCT03107611
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%, Placebo Cream
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
8 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
25
States / cities
Boynton Beach, Florida • Coral Gables, Florida • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 18, 2026, 1:05 AM EDT
Terminated Phase 2 Interventional Results available

Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

NCT00895895
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo, SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg, Donepezil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
37
States / cities
Phoenix, Arizona • Costa Mesa, California • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 18, 2026, 1:05 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate Efficacy and Safety of a New Suffocating Head Lice Product.

NCT05378477
View directory record Official record
Conditions
Head Lice, Pediculosis Capitis
Interventions
X92001752, RID Super Max Solution, Nix Crème, Pouxit Végétal
Device · Drug
Lead sponsor
Oystershell NV
Industry
Eligibility
1 Year and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 18, 2026, 1:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer

NCT04406831
View directory record Official record
Conditions
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms
Interventions
Blood draw
Procedure
Lead sponsor
Nuvance Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decreasing Loneliness to Optimize Pain Care

NCT06285032
View directory record Official record
Conditions
Loneliness, Opioid Use
Interventions
Cognitive Behavior Therapy (CBT), Social Navigation Group, Controlled Group
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

NCT03287791
View directory record Official record
Conditions
Rosacea
Interventions
Generic Azelaic Acid Foam, Finacea® (Azelaic Acid) Foam, Vehicle Foam, Cleanser, Sunscreen, Towel, Moisturizing Lotion
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
26
States / cities
Encino, California • La Mesa, California • Brandon, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Program to Increase Physical Activity Among Blacks

NCT00991731
View directory record Official record
Conditions
Physical Activity
Interventions
Faith-based, Non-faith-based
Behavioral
Lead sponsor
Melicia Whitt-Glover
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
496 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Not applicable Interventional

Nicotine Pharmacokinetics and Subjective Effects of Oral Nicotine Products Relative to Smokeless Tobacco in Adult Users

NCT06691386
View directory record Official record
Conditions
Tobacco Use
Interventions
Test Product A, Test Product B, Test Product C, Test Product D, Test Product E, Reference Product F: Subjects' OBMST
Other
Lead sponsor
Altria Client Services LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Bentonville, Arkansas • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Not applicable Interventional

Cementless Alumina-Alumina Total Hip and Hybrid

NCT00764530
View directory record Official record
Conditions
Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Avascular Necrosis
Interventions
Alumina/Alumina, Standard
Device
Lead sponsor
Encore Medical, L.P.
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
3
States / cities
Newport Beach, California • Charleston, South Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Not applicable Interventional

Lifestyle Management of CKD in Obese Diabetic Patients

NCT02276742
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Chronic Kidney Disease (CKD)
Interventions
Social Cognitive Theory, Monitoring
Behavioral · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 18, 2026, 1:05 AM EDT
Enrolling by invitation Not applicable Interventional

Patient-centered Precision Medicine Lab Result Communication for Older Adults

NCT07391904
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Health Communication, Patient Comprehension
Interventions
Chronic Kidney Disease (CKD) Lab Result Communication Tool
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 18, 2026, 1:05 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Asymptomatic and Pre-symptomatic Transmission of SARS-CoV-2 in a Community Congregant Setting

NCT05145803
View directory record Official record
Conditions
COVID-19, SARS-CoV2 Infection
Interventions
Polyvinylalcohol strip [diagnostic]
Device
Lead sponsor
Colorado School of Public Health
Other
Eligibility
18 Years and older
Enrollment
3,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis

NCT02160665
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tazarotene Cream, 0.05%, Vehicle, Reference: Tazorac Cream, 0.05%
Drug
Lead sponsor
G & W Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
866 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Study to Investigate the Tooth Stain Removal Efficacy of Two Experimental Toothpastes Compared to a Standard Toothpaste When Used Twice Daily for 8 Weeks

NCT05459558
View directory record Official record
Conditions
Oral Hygiene
Interventions
Experimental Dentifrice 1, Experimental Dentifrice 2, Reference Dentifrice
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 18, 2026, 1:05 AM EDT
Recruiting Not applicable Interventional

Influence of Spinal Stimulation Frequency on Spasticity, Motor Control, and Pain After Spinal Cord Injury

NCT06214208
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Transcutaneous Spinal Stimulation
Other
Lead sponsor
Shepherd Center, Atlanta GA
Other
Eligibility
16 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

NCT00642278
View directory record Official record
Conditions
Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
Interventions
Canagliflozin (JNJ-28431754), Sitagliptin, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adolescent Depression: Video Ads on Instagram

NCT05755165
View directory record Official record
Conditions
Depression, Stigmatization
Interventions
Depression, Depression, adjusted, Control
Behavioral
Lead sponsor
Yale University
Other
Eligibility
14 Years to 18 Years
Enrollment
1,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

NCT02839200
View directory record Official record
Conditions
Insomnia Disorder
Interventions
ACT-541468 5 mg, ACT-541468 10 mg, ACT-541468 25 mg, Zolpidem, Placebo 1, Placebo 2
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Santa Monica, California • Upland, California • Brandon, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Not applicable Interventional Results available

Personalized Dietary Management in Type 2 Diabetes

NCT05046886
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Standardized, Usual Care Control (UCC), Personalized Guidance to Minimize Postprandial Glycemic Response (PPGR)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 80 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 18, 2026, 1:05 AM EDT
Completed Not applicable Interventional

EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures

NCT01681225
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Esophageal-pressure guided mechanical ventilation, High PEEP mechanical ventilation
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
La Jolla, California • Stanford, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 18, 2026, 1:05 AM EDT
Recruiting No phase listed Observational

EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)

NCT03369821
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Beta Cell Loss and Immune Function, Immune Function with RNAseq
Diagnostic Test · Other
Lead sponsor
University of Exeter
Other
Eligibility
Up to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 18, 2026, 1:05 AM EDT